Dosing reference
Peptide dosing: reference navigator
Every molecule in the catalog has its own reference of doses studied in published research, with source citations. This page gathers them in one place: pick a peptide and jump to its scheme, the monograph covering its mechanism, the product card, or the batch COA archive.
All materials concern research use only. The references describe doses used in published studies; they are not usage instructions and not medical advice.
Accessories
Tissue Repair
BMP-7 (OP-1)Recombinant BMP-7 was used in people as a surgical implant with a carrier, not as a systemic dose. What that means for the research reagent.Dosing reference →BPC-157How to reconstitute BPC-157 with bacteriostatic water and which dose ranges research sources mention. No official human protocol, research use only.Dosing reference →BPC-157 + TB-500 BlendThere is no verified published human regimen for the BPC-157 + TB-500 combination.Dosing reference →GHK-CuThe clinical publication concerns a topical complex; no verified injectable regimen exists for this exact product.Dosing reference →
Weight loss / GLP-1 (incretins)
CagrilintideAdults were studied with weekly subcutaneous doses, including in combination with semaglutide 2.4 mg.Dosing reference →LiraglutideAdult schedule with gradual dose escalation.Dosing reference →RetatrutideHuman studies evaluated several weekly target doses; no universal escalation schedule has been established.Dosing reference →SemaglutideAdult schedule with gradual increases when needed.Dosing reference →
Anti-Aging
EpitalonEpitalon reference dosing. Reference schedule. For research use only.Dosing reference →EpithalaminCourse schedule: 10 mg/day intramuscularly for 10 days or 5 mg/day for up to 20 days, with the course repeated 2–3 times a year.Dosing reference →FOXO4-DRIA brief reference to studied FOXO4-DRI regimens. No validated human protocol exists — only preclinical in vivo mouse regimens (5 mg/kg, every other day) are shown, with primary-source citations.Dosing reference →GlutathioneGlutathione is poorly absorbed orally, so protocols describe IM or SubQ dosing (200–1200 mg weekly) and IV infusions of 500–1400 mg.Dosing reference →
GH Secretagogues
GHRP-2A reference point from described protocols: start at 100 mcg once daily, standard regimen 100–200 mcg 1–3 times daily, maximum 300 mcg per injection.Dosing reference →GHRP-6The described subcutaneous regimen: 100–300 mcg per injection three times a day, escalated week by week. Several daily injections reflect the peptide's short half-life.Dosing reference →IpamorelinIpamorelin reference dosing. Reference schedule. For research use only.Dosing reference →MK-677 (Ibutamoren)The main MK-677 regimen is 10–20 mg orally once daily. The largest published study, which ran for two years, used 25 mg with no dose escalation.Dosing reference →
Metabolic Peptides
HGH Fragment 176-191Human clinical data exist only for AOD9604, a modified analogue (Tyr-hGH 177-191): oral 0.25–54 mg/day, intravenous 25–400 µg/kg. There are no human clinical trials of the unmodified 176-191 fragment; the 250–500 µg/day subcutaneous schedule on this page comes from community protocols.Dosing reference →PXL770PXL770 is a direct AMPK activator that reached phase 2. Which oral doses were studied in NAFLD and how to handle the compound in the lab.Dosing reference →
IGF Pathway
Melanocortin agonists
Myostatin / Activin Pathway
ACE-083ACE-083 had a real clinical program of local intramuscular injections. What the phase 2 trials showed and why it is not approved.Dosing reference →Bimagrumab (BYM338)Bimagrumab is an anti-activin-receptor antibody with a large clinical program. Which intravenous doses were studied and what the trials showed.Dosing reference →
GHRH Analogues
CJC-1295 with DACThe half-life reaches ~6–8 days, so regimens are described as once weekly (1–2 mg). In a 2006 study, IGF-I stayed elevated for 9–11 days after a single injection.Dosing reference →TesamorelinIn the clinical trial by Falutz and colleagues (2007), the dose was fixed: 2 mg subcutaneously once daily for 26 weeks, in adults with HIV-associated lipodystrophy.Dosing reference →
Mitochondria
HumaninThere is no established human dosing protocol for humanin. This reference collects only preclinical regimens studied in animals (mice): HNG 4 mg/kg intraperitoneally twice weekly (Yen 2020) and native humanin 0.7–2 mg/kg/day intraperitoneally (Hoang 2010). Every value is tied to a published DOI-cited source; there are no human equivalents.Dosing reference →L-CarnitineLyophilized powder, 600 mg per vial. Published injectable regimens: IM 500 mg twice daily for 7 days; IV 50 mg/kg/day, or 10–20 mg/kg after each dialysis.Dosing reference →MOTS-cNo validated human regimen has been established; human interventional data are unavailable.Dosing reference →SS-31Regimen studied in adults with primary mitochondrial myopathy.Dosing reference →
NAD+ / Metabolic Longevity
5-Amino-1MQNo validated human regimen has been established; available data are preclinical.Dosing reference →NAD+A subcutaneous reference generalized from longevity-practice protocols.Dosing reference →Nicotinamide Riboside (NR)NR is a NAD+ precursor with the most human data on this list. Which oral doses have been studied and how to store the compound.Dosing reference →
Anti-Fibrosis
AC-SDKPAC-SDKP dosing comes almost entirely from preclinical infusion studies, not human trials. What the data show, and why there's no established human protocol.Dosing reference →B7-33A brief reference to the studied B7-33 regimens. Preclinical (mouse) data only; no validated human dosing protocol exists.Dosing reference →
Endurance / ERR Agonists
SLU-PP-332A brief reference on the studied SLU-PP-332 regimens. All data is preclinical (mice, intraperitoneal); no confirmed human protocol exists, and mg/kg doses do not transfer to humans.Dosing reference →SLU-PP-915SLU-PP-915 is an ERR agonist from a purely preclinical series. There is no human data at all: we explain what that means for dosing.Dosing reference →
Nerve / Neuroregeneration
ARA-290Regimen studied in adults with type 2 diabetes and neuropathic symptoms.Dosing reference →DSIP (Delta sleep-inducing peptide)In human clinical studies DSIP was usually given intravenously, most often at 25 nmol/kg (≈21 mcg/kg). The subcutaneous 100–500 mcg evening schedule comes from community protocols. The evidence base is thin and largely preclinical.Dosing reference →MIF-1 (Pro-Leu-Gly-NH₂)What the general and published literature says about dosing the MIF-1 tripeptide, how it is reconstituted, and why no approved human protocol exists.Dosing reference →SelankRegimens from Russian studies and protocols: 250–300 mcg per application, up to 2.25 mg/day total, courses up to 14 days.Dosing reference →
Healing & Regeneration
Documentation & references
| Document | Description | Last updated | Format |
|---|---|---|---|
| Bacteriostatic Water: Handling, Reconstitution and Storage | A practical guide: physical form, peptide reconstitution chemistry, storage of lyophilised vs reconstituted material, stability and lab handling. | Page | |
| About Longeva | Longeva is a Kyiv research-peptide store. Independent per-batch COAs, DOI-cited wiki, RUO only. | Page | |
| Longeva editorial policy | How Longeva cites research, where the RUO line sits, and who signs the copy. No medical advice, no invented doses. | Page | |
| Cagrilintide: form, reconstitution and storage | A practical guide to handling cagrilintide: lyophilised form, reconstitution with bacteriostatic water, storage and stability. Research use. | Page | |
| MOTS-c: form, reconstitution and storage | A practical guide to handling MOTS-c: physical form, reconstitution chemistry, storage of lyophilized and reconstituted material, stability. Research use, no human dosing. | Page | |
| 5-Amino-1MQ: handling, reconstitution and storage | A practical reference for laboratory handling of 5-Amino-1MQ: form, reconstitution chemistry, storage and stability. | Page | |
| NAD+: Form, Reconstitution and Storage (Research Format) | A practical handling reference for NAD+: physical form, reconstitution chemistry with bacteriostatic water, storage of lyophilizate versus solution, stability and lab applications. | Page | |
| Glutathione (GSH): Form, Reconstitution and Lab Handling | A practical guide to the physical form, reconstitution chemistry, storage and stability of the glutathione research reagent. | Page | |
| Semaglutide: reagent form, reconstitution and storage | A practical guide to handling semaglutide as a reagent: physical form, reconstitution with bacteriostatic water, storage of lyophilized versus reconstituted material, stability, and research applications. | Page | |
| Tirzepatide: form, reconstitution and lab handling | A practical look at tirzepatide's physical form, reconstitution chemistry with bacteriostatic water, storage of lyophilizate vs. solution, and stability for research use. | Page | |
| Retatrutide (LY3437943): physical form, storage and reconstitution in the lab | A researcher's practical reference: lyophilized powder, reconstitution chemistry with bacteriostatic water, storage and stability of retatrutide. For research use only. | Page | |
| KLOW blend — lab handling, reconstitution and storage | Practical handling notes for the KLOW research blend: form, reconstitution chemistry with bacteriostatic water, storage of lyophilized versus reconstituted material, and stability. | Page |
What is a dosing reference?
A dosing reference is an overview of published research on one molecule: the dose ranges, administration protocols and notes reported by the study authors, each with a source citation. All materials concern research use only; they are not usage instructions and not medical advice.
FAQ
Where do the doses in the references come from?
From published research: each reference lists the ranges the authors of specific studies used, with citations. A reference describes the research context, not a recommendation.
Why does this page show no numbers itself?
Doses depend on the molecule, the model and the protocol of a specific study, so a number taken out of context misleads. This page routes to each molecule's full reference, where ranges appear together with their sources.
How do I check the purity of a specific batch?
Batches are accompanied by certificates of analysis (COA) from independent third-party laboratories. Open the COA archive, find the product or lot number, and review the report with the measured purity.